Appointment of Corporate Adviser and Broker

EDX Medical Group PLC

19 June 2023

 

EDX Medical Group PLC - Appointment of Corporate Adviser and Broker

EDX Medical Group PLC · EDX

19 June 2023

EDX Medical Group PLC ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases, is pleased to announce the appointment of Oberon Capital as the Company's Corporate Adviser and sole broker with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.

Contacts:

EDX Medical PLC
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith (Director) Gary McQueen (Senior Consultant)	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]

Notes for Editors:

About EDX Medical Group

www.edxmedical.co.uk

EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and a 100%-owned subsidiary "Torax Biosciences Ltd" (www.toraxbiosciences.co.uk) in Ireland.   

EDX Medical, provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

 

END